ChinaBio Today -- Pfizer (NYSE: PFE) announced two new collaborations with China academic institutions last week. Neither one was targeted at developing a specific drug candidate. Instead, their goal appeared to be building long-term relationships with academic leaders in China’s scientific community. Even though it has built a large, self-contained R&D center in Shanghai, Pfizer seems intent upon forging ties with the greater world of China biopharma.
